Concepts (111)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myofibroma | 2 | 2020 | 14 | 1.360 |
Why?
|
| Thyroid Neoplasms | 5 | 2021 | 1866 | 0.940 |
Why?
|
| Mammary Analogue Secretory Carcinoma | 1 | 2021 | 9 | 0.820 |
Why?
|
| Neoplasms, Muscle Tissue | 1 | 2021 | 22 | 0.800 |
Why?
|
| Angiomatosis | 1 | 2021 | 26 | 0.790 |
Why?
|
| Vascular Malformations | 1 | 2022 | 83 | 0.770 |
Why?
|
| Myofibromatosis | 1 | 2020 | 7 | 0.760 |
Why?
|
| Hemangioma | 1 | 2022 | 154 | 0.740 |
Why?
|
| Lymphatic Vessels | 1 | 2021 | 143 | 0.710 |
Why?
|
| Sirolimus | 3 | 2022 | 814 | 0.640 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2021 | 489 | 0.580 |
Why?
|
| Thrombocytopenia | 1 | 2021 | 846 | 0.540 |
Why?
|
| Quinolines | 1 | 2018 | 383 | 0.520 |
Why?
|
| Phenylurea Compounds | 1 | 2018 | 580 | 0.510 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 1375 | 0.500 |
Why?
|
| Paired Box Transcription Factors | 1 | 2014 | 134 | 0.480 |
Why?
|
| Lymphatic Abnormalities | 2 | 2022 | 29 | 0.420 |
Why?
|
| Carcinoma | 1 | 2021 | 2578 | 0.360 |
Why?
|
| Carcinogenesis | 1 | 2014 | 1026 | 0.310 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 2020 | 328 | 0.300 |
Why?
|
| Carcinoma, Papillary | 2 | 2020 | 584 | 0.280 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2014 | 2359 | 0.260 |
Why?
|
| Child | 11 | 2022 | 29154 | 0.250 |
Why?
|
| Infant | 6 | 2022 | 13310 | 0.230 |
Why?
|
| Skin Neoplasms | 1 | 2020 | 4654 | 0.230 |
Why?
|
| p120 GTPase Activating Protein | 1 | 2022 | 10 | 0.210 |
Why?
|
| Neoplasms | 2 | 2022 | 15193 | 0.210 |
Why?
|
| Thyroidectomy | 3 | 2021 | 486 | 0.210 |
Why?
|
| Antineoplastic Agents | 3 | 2021 | 14289 | 0.210 |
Why?
|
| Capillaries | 1 | 2022 | 99 | 0.210 |
Why?
|
| Chylothorax | 1 | 2021 | 36 | 0.200 |
Why?
|
| Endothelium, Lymphatic | 1 | 2021 | 14 | 0.200 |
Why?
|
| Salivary Glands | 1 | 2021 | 130 | 0.200 |
Why?
|
| Peritonitis | 1 | 2021 | 89 | 0.190 |
Why?
|
| Sulfones | 1 | 2021 | 143 | 0.190 |
Why?
|
| Desmoplastic Small Round Cell Tumor | 1 | 2021 | 86 | 0.190 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 1 | 2020 | 47 | 0.180 |
Why?
|
| Pleural Effusion | 1 | 2021 | 201 | 0.180 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2022 | 521 | 0.180 |
Why?
|
| Child, Preschool | 4 | 2021 | 16273 | 0.180 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2022 | 371 | 0.180 |
Why?
|
| Myoblasts | 1 | 2019 | 72 | 0.170 |
Why?
|
| Humans | 20 | 2022 | 261506 | 0.170 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2020 | 132 | 0.170 |
Why?
|
| Thyroid Gland | 1 | 2021 | 355 | 0.170 |
Why?
|
| Adolescent | 7 | 2021 | 31252 | 0.170 |
Why?
|
| Syndrome | 1 | 2022 | 1351 | 0.160 |
Why?
|
| Mycoses | 1 | 2021 | 386 | 0.150 |
Why?
|
| Biomarkers, Tumor | 3 | 2021 | 10331 | 0.150 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2021 | 475 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2022 | 2054 | 0.150 |
Why?
|
| Sequence Analysis, RNA | 1 | 2020 | 651 | 0.150 |
Why?
|
| Mediastinal Neoplasms | 1 | 2020 | 423 | 0.140 |
Why?
|
| Mutation | 4 | 2022 | 15179 | 0.140 |
Why?
|
| Testicular Neoplasms | 1 | 2020 | 529 | 0.140 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2021 | 755 | 0.140 |
Why?
|
| Rhabdomyosarcoma | 1 | 2019 | 341 | 0.140 |
Why?
|
| Treatment Outcome | 4 | 2022 | 32848 | 0.130 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2022 | 1546 | 0.130 |
Why?
|
| DNA, Neoplasm | 1 | 2020 | 1910 | 0.130 |
Why?
|
| Neuroendocrine Tumors | 1 | 2021 | 634 | 0.120 |
Why?
|
| Developmental Biology | 1 | 2014 | 21 | 0.120 |
Why?
|
| Peritoneal Neoplasms | 1 | 2021 | 821 | 0.120 |
Why?
|
| Drosophila | 1 | 2019 | 839 | 0.120 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 1331 | 0.120 |
Why?
|
| Surgical Procedures, Operative | 1 | 2017 | 383 | 0.110 |
Why?
|
| Drosophila Proteins | 1 | 2019 | 858 | 0.110 |
Why?
|
| Male | 6 | 2021 | 123000 | 0.100 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 4744 | 0.100 |
Why?
|
| Molecular Targeted Therapy | 1 | 2021 | 2330 | 0.100 |
Why?
|
| Combined Modality Therapy | 2 | 2020 | 8865 | 0.090 |
Why?
|
| Hematologic Neoplasms | 1 | 2021 | 1870 | 0.090 |
Why?
|
| Pyrimidines | 1 | 2021 | 3518 | 0.080 |
Why?
|
| Retrospective Studies | 6 | 2022 | 37905 | 0.080 |
Why?
|
| Cell Differentiation | 1 | 2019 | 4078 | 0.080 |
Why?
|
| Female | 7 | 2021 | 141928 | 0.080 |
Why?
|
| Infant, Newborn | 2 | 2020 | 8223 | 0.080 |
Why?
|
| Texas | 1 | 2017 | 6311 | 0.070 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 14889 | 0.070 |
Why?
|
| Ovarian Neoplasms | 1 | 2020 | 4638 | 0.060 |
Why?
|
| Sclerotherapy | 1 | 2022 | 48 | 0.050 |
Why?
|
| Octreotide | 1 | 2021 | 118 | 0.050 |
Why?
|
| Receptors, Peptide | 1 | 2021 | 86 | 0.050 |
Why?
|
| Radioisotopes | 1 | 2021 | 177 | 0.050 |
Why?
|
| Radionuclide Imaging | 1 | 2021 | 660 | 0.040 |
Why?
|
| Cytogenetic Analysis | 1 | 2020 | 568 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2020 | 447 | 0.040 |
Why?
|
| Iodine Radioisotopes | 1 | 2020 | 371 | 0.040 |
Why?
|
| Teratoma | 1 | 2020 | 236 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 11538 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2021 | 15694 | 0.040 |
Why?
|
| Hospitals, Pediatric | 1 | 2021 | 773 | 0.040 |
Why?
|
| Critical Illness | 1 | 2021 | 714 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2021 | 795 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2021 | 1301 | 0.030 |
Why?
|
| Antifungal Agents | 1 | 2021 | 834 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 15862 | 0.030 |
Why?
|
| Disease Management | 1 | 2020 | 1052 | 0.030 |
Why?
|
| Animals | 2 | 2019 | 59536 | 0.030 |
Why?
|
| Prognosis | 2 | 2020 | 21713 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2021 | 2173 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 2594 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2020 | 4844 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2019 | 2295 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 3821 | 0.020 |
Why?
|
| Algorithms | 1 | 2021 | 3890 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2021 | 5542 | 0.020 |
Why?
|
| Adult | 2 | 2021 | 77950 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2019 | 8873 | 0.010 |
Why?
|
| Young Adult | 1 | 2020 | 21445 | 0.010 |
Why?
|
| Mice | 1 | 2019 | 34495 | 0.010 |
Why?
|